REFERENCES
1. Siegel RL, Miller KD, Fuchs HE, Jemal A. 2022. Cancer statistics, 2022. CA Cancer J Clin . 72(1):7-33.
2. Konstantinidis IT, Warshaw AL, Allen JN, et al. 2013. Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a ”true” R0 resection? Ann Surg . 257(4):731-736.
3. Ryan DP, Hong TS, Bardeesy N. 2014. Pancreatic adenocarcinoma.N Engl J Med . 371(11):1039-1049.
4. Oweira H, Petrausch U, Helbling D, et al. 2017. Prognostic value of site-specific metastases in pancreatic adenocarcinoma: A Surveillance Epidemiology and End Results database analysis. World J Gastroenterol . 23(10):1872-1880.
5. Kurahara H, Maemura K, Mataki Y, et al. 2020. Lung recurrence and its therapeutic strategy in patients with pancreatic cancer.Pancreatology . 20(1):89-94.
6. Kumar A, Dagar M, Herman J, Iacobuzio-Donahue C, Laheru D. 2015. CNS involvement in pancreatic adenocarcinoma: a report of eight cases from the Johns Hopkins Hospital and review of literature. J Gastrointest Cancer . 46(1):5-8.
7. Yamaguchi K, Tanaka M. 2011. EBM-based Clinical Guidelines for Pancreatic Cancer 2009 from the Japan Pancreas Society: a synopsis.Jpn J Clin Oncol . 41(7):836-840.
8. Murakami Y, Uemura K, Sudo T, et al. 2008. Adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma.Am J Surg . 195(6):757-762.
9. Murakami Y, Uemura K, Sudo T, et al. 2009. Impact of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for adenocarcinoma of the body or tail of the pancreas. J Gastrointest Surg . 13(1):85-92.
10. Buscail L. 2017. Commentary: Pancreatic cancer: is the worst to come? Int J Epidemiol . 46(6):1774-1775.
11. Takahashi M, Nojima H, Kuboki S, et al. 2020. Comparing prognostic factors of Glut-1 expression and maximum standardized uptake value by FDG-PET in patients with resectable pancreatic cancer.Pancreatology . 20(6):1205-1212.
12. Miyazaki M, Yoshitomi H, Shimizu H, et al. 2014. Repeat pancreatectomy for pancreatic ductal cancer recurrence in the remnant pancreas after initial pancreatectomy: is it worthwhile? Surgery . 155(1):58-66.
13. Conroy T, Desseigne F, Ychou M, et al. 2011. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med . 364(19):1817-1825.
14. Von Hoff DD, Ervin T, Arena FP, et al. 2013. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med . 369(18):1691-1703.
15. Takahashi M, Yoshitomi H, Kato A, et al. 2019. A case of successfully resected metachronous gastric and gallbladder metastases from pancreatic body cancer. Surg Case Rep . 5(1):21.
16. Zheng B, Ohuchida K, Yan Z, Okumura T, Ohtsuka T, Nakamura M. 2017. Primary Recurrence in the Lung is Related to Favorable Prognosis in Patients with Pancreatic Cancer and Postoperative Recurrence.World J Surg . 41(11):2858-2866.
17. Okui M, Yamamichi T, Asakawa A, Harada M, Horio H. 2017. Resection for Pancreatic Cancer Lung Metastases. Korean J Thorac Cardiovasc Surg . 50(5):326-328.
18. Lemke J, Scheele J, Kapapa T, Wirtz CR, Henne-Bruns D, Korn{Lemke m, M. 2013. Brain metastasis in pancreatic cancer. Int J Mol Sci . 14(2):4163-4173.
19. Matsumoto H, Yoshida Y. 2015. Brain metastasis from pancreatic cancer: A case report and literature review. Asian J Neurosurg . 10(1):35-39.
20. Oka Y, Takano S, Kouchi Y, et al. 2021. Simultaneous brain and lung metastases of pancreatic ductal adenocarcinoma after curative pancreatectomy: a case report and literature review. BMC Gastroenterol . 21(1):9.
21. Sasaki T, Sato T, Nakai Y, Sasahira N, Isayama H, Koike K. 2019. Brain metastasis in pancreatic cancer: Two case reports. Medicine (Baltimore) . 98(4):e14227.